Inclacumab

Inclacumab (Anti-Human selectin P Recombinant Antibody) is a human monoclonal IgG4 antibody selectively targets P-selectin with a Kd value of 9.9 nM. Inclacumab inhibits P-selectin glycoprotein ligand 1 (PSGL-1) mimetic peptide bind with P-selectin with an IC50 value of 1.9 μg/mL and strongly inhibits cell adhesion[1][2][3].

Product Specifications

CAS Number

[1256258-86-2]

Product Name Alternative

Anti-Human selectin P Recombinant Antibody

UNSPSC

12352203

Target

P-selectin

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/inclacumab.html

Purity

99.80

Solubility

10 mM in DMSO

Smiles

[Inclacumab]

Molecular Weight

(145.42 kDa)

References & Citations

[1]Tarasev M, et al. S107: P-SELECTIN INHIBITOR INCLACUMAB REDUCES CELL ADHESION IN AN IN-VITRO ASSAYS SHOWING POTENTIAL FOR PREVENTION OF VASO-OCCLUSION EVENTS IN SICKLE CELL DISEASE. Hemasphere. 2022 Jan 31;6 (Suppl) :3-4.|[2]Xin Geng, et al. Inclacumab, a Fully Human Anti-P-Selectin Antibody, Directly Binds to PSGL-1 Binding Region and Demonstrates Robust and Durable Inhibition of Cell Adhesion. Blood (2020) 136 (Supplement 1) : 10–11.|[3]Kling D, et al. Pharmacological control of platelet-leukocyte interactions by the human anti-P-selectin antibody inclacumab--preclinical and clinical studies. Thromb Res. 2013 May;131 (5) :401-10.